Prevalence and outcomes of pregnancies in women living with HIV over a 20-year period: The EuroSIDA study, 1996 to 2015


a Department of Adults’ Infectious Diseases, Medical University of Warsaw, Warsaw, Poland,
b Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, UK,
c CHIP Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark,
d Hospital J.M. Ramos Mejia, Buenos Aires, Argentina,
e Novgorod Centre for AIDS prevention and control, Novgorod the Great, Russian Federation,
f Gomel State Medical University, Gomel, Belarus,
g Centre for HIV/AIDS & Infectious Diseases, Kaliningrad, Russian Federation,
h Gomel Regional Centre for Hygiene, Gomel, Belarus,
i J.W. Goethe University Hospital, Frankfurt, Germany,
j Department of Infectious Diseases, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain,
k Wojewodzki Szpital Zakazny, Warsaw, Poland,
l ASST Santi Paolo e Carlo, University of Milan, Milan, Italy,
m Aarhus Universitetshospital, Skejby, Denmark,
n Clinic of Infectious Diseases and Hepatology, Medical University of Lodz, Łódź, Poland,
o Kharkov State Medical University, Kharkov, Ukraine,
p Servicio Enfermedades Infecciosas, Hospital Universitario Ramón y Cajal, Madrid, Spain,
q Lviv Regional HIV/AIDS Prevention and Control Center, Lviv, Ukraine,
r CHU Nice Hopital de l’ Archet 1, Nice, France,
s Department of Medicine, University Hospital Basel, Basel, Switzerland,
t Ghent University Hospital, Ghent, Belgium,
u Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy.

Running Title: Pregnancies in women with HIV in Europe

Main text word count: 1797 words
Abstract word count: 243 words
Number of Figures and Tables: 2 Figures
Number of references: 28
Supplemental Digital Content: 4 Items

Corresponding author:

Annegret Pelchen-Matthews
Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME),
Institute for Global Health, Faculty of Population Health Sciences,
University College London, Rowland Hill Street, London NW3 2PF
e-mail a.pelchen-matthews@ucl.ac.uk
Funding Statement:

EuroSIDA has received funding from Viiv Healthcare LLC, Janssen Scientific Affairs, Janssen R&D, Bristol-Myers Squibb Company, Merck Sharp & Dohme Corp, Gilead Sciences and the European Union’s Seventh Framework Programme for research, technological development and demonstration under EuroCoord grant agreement no 260694. The participation of centres from Switzerland has been supported by The Swiss National Science Foundation (Grant 148522). The study is also supported by a grant [grant number DNRF126] from the Danish National Research Foundation and by the International Cohort Consortium of Infectious Disease (RESPOND).
Abstract

Objective:

To evaluate time trends in pregnancies and pregnancy outcomes among women living with HIV in Europe.

Design:

European multicentre prospective cohort study.

Methods:

EuroSIDA has collected annual cross-sectional audits of pregnancies between 1996 and 2015. Pregnancy data were extracted and described. Odds of pregnancy were modelled, adjusting for potential confounders using logistic regression with generalised estimating equations.

Results:

Of 5535 women aged 16 to <50 years, 4217 (76.2%) had pregnancy information available, and 912 (21.6%) reported 1315 pregnancies. The proportions with at least one pregnancy were 28.1% (321/1143) in East, 24.5% (146/596) in North, 19.8% (140/706) in West/Central, 19.3% (110/569) in Central East and 16.2% (195/1203) in South Europe. Overall 319 pregnancies (24.3%) occurred in 1996-2002, 576 (43.8%) in 2003-2009 and 420 (31.9%) in 2010-2015. After adjustment, the odds of pregnancy were lower in 1996-2002, in South, Central East and East compared to West/Central Europe, in older women, those with low CD4 counts or with prior AIDS, and higher in those with a previous pregnancy or who were HCV positive.

Outcomes were reported for 999 pregnancies in 1996-2014, with 690 live births (69.1%), seven stillbirths (0.7%), 103 spontaneous (10.3%) and 199 medical abortions (19.9%).

Conclusions:

Around 20% of women in EuroSIDA reported a pregnancy, with most pregnancies after 2002, when more effective antiretroviral therapy became available. Substantial differences were seen between European regions. Further surveillance of pregnancies and outcomes among women living with HIV is warranted to ensure equal access to care.
Key words: Human Immunodeficiency Virus, Acquired Immunodeficiency Syndrome, anti-retroviral therapy, pregnancy, birth outcome.
Introduction

Women contribute half of the persons living with HIV worldwide [1,2] and around 30% of those in Europe, where >1/3 of new diagnoses are now among women [3]. The majority of women living with HIV (WLWH) are of childbearing potential [3]. Nonetheless, gender disparities remain in access to treatment, adherence, virological suppression and retention in care, with impacts on perceived stigma and quality of life [4,5].

Although the introduction of antiretroviral therapy (ART) has significantly reduced mother-to-child transmission of HIV in Europe [6], guidelines still recommend avoiding certain antiretrovirals in women of reproductive age[7,8], which may limit access to certain modern ART components in some regions [9-11], resulting in reduced adherence and poorer virologic outcomes. There is a need to integrate HIV treatment with sexual and reproductive health to take account personal fertility and procreational plans [12-14].

There is little epidemiological information on the overall trends in pregnancies among WLWH and factors that impact on the probability of pregnancy. Here we aimed to evaluate trends and outcomes of pregnancies among WLWH in the European region to inform health interventions and ascertain equal access to family planning.

Methods

EuroSIDA is a multinational prospective observational cohort study that has systematically collected data for >23,000 HIV-positive individuals in 35 European countries, Israel and Argentina since 1994 ([https://www.chip.dk/Studies/EuroSIDA](https://www.chip.dk/Studies/EuroSIDA),[15]). All individuals gave informed consent at enrolment.

Data on pregnancies in women of reproductive age (≥16 and <50 years old) were collected between 1996 and 2015 as annual audits, with women asked whether they had been pregnant in the previous year and the outcome of the pregnancy (as birth of a HIV-negative child, HIV-positive child, or child with unknown HIV status, stillbirth, spontaneous abortion, medical abortion, still pregnant, or unknown). As no dates of conception or delivery were available, incidence rates for pregnancies could not be calculated. Pregnancy information was
extracted in each study year, with the baseline date for each record set to 01 January of the year. For outcomes reported as ‘still pregnant’, records were updated with outcome information in the following year, else the outcome was recorded as unknown. The collection of pregnancy data ended in 2015, with no outcome information available for pregnancies in 2015.

Trends in pregnancies were summarised for each woman, stratified by time period (TP1, 1996-2002; TP2, 2003-2009 and TP3, 2010-2015), with variables as on 1st January of the year when pregnancy information was first available for each participant. Descriptive tabulations show proportions of individuals, or medians and inter-quartile range (IQR). Confidence intervals (CI) are 95%, and P-values two-sided, with P<0.05 considered significant.

To investigate factors associated with pregnancy, each record of pregnancy information was treated as a separate data item. Odds of pregnancy were modelled using logistic regression with generalised estimating equations (GEE) to account for repeated pregnancy information within women. An unknown category was used to account for missing data for categorical variables. Multivariable models included all factors with type-3 P-values <0.1 in univariable analysis that were not considered collinear.

Analyses were conducted using Statistical Analysis Software (SAS) version 9.4 (SAS Institute Inc., Cary, North Carolina, USA).
Results

Of 5535 women of reproductive age enrolled in EuroSIDA between 1996 and 2015, 4217 (76.2%) reported pregnancy information (pregnant in the previous year, yes/no) in at least one year. Overall, 23,380 annual entries of pregnancy information were collected (median of 4, IQR 2-7 audits/woman), with altogether 1315 pregnancies; 912/4217 women (21.6%) reported at least one pregnancy.

Trends in the reporting of pregnancy information and pregnancies are summarized in Figure 1. The proportion of women who reported ≥1 pregnancy increased from 15.3% (CI 13.6-17.2%) in TP1 to 17.3% (15.9-18.8%) in TP2, and declined to 12.6% (11.4-13.9%) in TP3 (Figure 1a), but this varied for different regions of Europe (Figure 1b). The highest proportions of women with pregnancy information were in Central East (87.9%) and East Europe (81.8%) and the lowest in West/Central Europe (62.2%). Of the women who reported a pregnancy, most resided in East Europe (321, 35.2%) and in the South (195, 21.4%). Figure 1c summarises the numbers of women with at least one pregnancy, by time period and region of Europe. As EuroSIDA did not enrol participants in Central East Europe until 1999 and in East Europe until 2001, there were few women from East Europe under follow-up in TP1, but almost half of those (18/38, 47%) reported a pregnancy.

Characteristics of women under follow-up in the three time periods are shown in Supplementary Table S1. The median age of women when they first reported pregnancy information was 33 (IQR 29-39) years, and in all three time periods women who reported ≥1 pregnancy were younger than those who did not. Most women were of white ethnicity, 62% had acquired HIV heterosexually and 30% were injection drug users (IDUs). Pregnancies were more frequent in women with higher baseline or nadir CD4 counts. The proportion of women on any ART increased with time, but women with ≥1 pregnancy had lower rates of ART use than those who were not pregnant. Those with ≥1 pregnancy were also less likely to have a previous AIDS diagnosis than those without.

Of the 1315 pregnancies, 319 (24.3%) were reported in 1996-2002, 576 (43.8%) in 2003-2009 and 420 (31.9%) in 2010-2015. Factors associated with the odds of pregnancy are summarised in Figure 2 (see also Supplementary Table S2). After multivariable adjustment, the odds of pregnancy were lower in TP1 vs TP2 (adjusted odds ratio (aOR) 0.74; CI 0.62-0.89, P=0.0015). The odds of pregnancy also decreased with older age (aOR 0.53; CI 0.50-0.56 per 5 years older, P <0.0001). Higher odds of pregnancy were seen in those with a previous pregnancy reported in EuroSIDA (aOR 1.89; CI 1.59-2.24, P<0.0001). After adjustment, the odds of pregnancy were similar in
West/Central and North Europe, and significantly lower in South, Central East and East Europe. The odds of pregnancy were higher in women diagnosed with HIV <2 years previously and in HCV co-infected women, while a prior AIDS-defining illness reduced the odds of pregnancy by around 40% (aOR 0.58; 0.47-0.71, P = <0.0001). There was no evidence that the change in pregnancies over time differed according to region of Europe (P for interaction = 0.94). Sensitivity analyses excluding Argentina as part of region South showed consistent results.

Of 1217 pregnancies between 1996-2014, outcomes were reported for 999 (82.2%). There were 690 live births (69.1%, of which 342 (49.6%) were HIV-negative, 23 (3.3%) HIV-positive and 325 (47.1%) of unknown HIV status), seven stillbirths (0.7%), 103 (10.3%) spontaneous and 199 (19.9%) medical abortions (Supplementary Figure S1).

The proportion of live births was lowest in TP1. The proportion of pregnancies ending in spontaneous or medical abortions decreased between TP1 and TP2, and for medical abortions also in TP3. The lowest proportion of live births was in South (49.6%) and North Europe (51.1%), where women also had lower odds of live birth (Supplementary Table S3 and Supplementary Figure S1c).

Discussion

We investigated trends in pregnancies in >4200 WLWH in Europe over a 20-year period. Around 22% of women reported at least one pregnancy. Most pregnancies occurred in 2003-2009, with a decline in recent years. The highest number of pregnancies were reported in East Europe, where 28% of women had ≥1 pregnancy, and the lowest in the South (16.2%). The odds of pregnancy were higher in younger women and those with a previous pregnancy, and lower in those with baseline or nadir CD4 counts <200 cells/µL, or with prior AIDS.

The increase in pregnancies in EuroSIDA after 2002 may also be related to more effective and less toxic forms of ART [16], with decreased morbidity and improved quality of life. In many clinics across Europe reproductive counselling is now integrated into HIV care [17] and WLWH are encouraged to make long-term family plans and conceive safely [18,19]. The later decline in pregnancies in TP3 reflects trends in the general population. In the European Union, birth rates were relatively constant between 1996 and 2018, apart from a modest increase in 2008-2010 [20]; fertility rates in women <30 years have fallen since 2001, but increased in women aged 30-34,
and the number of children per woman has declined [20]. We also observed an increase in age at pregnancy in WLWH, but women in East Europe were younger than elsewhere [15]. A recent increase in maternal age was also noted by other HIV cohorts in Europe [21,22].

Of the 1217 pregnancies reported to 2014, outcomes were reported for 999 (82.2%). Almost 70% of pregnancies resulted in a live birth, but 20% were reported as medical abortion, though the proportion of medical abortions decreased over the three time periods. Other studies also indicate termination rates may be high in WLWH [23], but data are scarce in Europe. Published research generally assumes HIV status is the only reason for ending a pregnancy [24,25]. As abortions can follow unintended pregnancies, it is important to ensure access to contraceptive counselling and modern contraception methods for WLWH in Europe. Furthermore, drug-drug interactions with antiretrovirals may reduce contraceptive effectiveness (see https://www.hiv-druginteractions.org/). A better knowledge of the factors that influence reproductive decision-making is necessary to improve services and policies to meet the needs and rights of WLWH in Europe.

This study is, to our knowledge, the first report of cross-sectional audits of pregnancies among WLWH across Europe. A strength of the study is that the audits were performed uniformly over almost 20 years and data collected with consistency and regular validation. There are also limitations. No pregnancy information was available for around 25% of the women of reproductive age, though a comparison of women with and without pregnancy information suggests that those who reported pregnancy information were broadly representative of the women in the cohort. We considered many potential confounders in our model, but there may be unmeasured or unknown confounders. Eastern Europe only joined EuroSIDA in 2001, with little data in TP1, and results should therefore be interpreted with caution [26]. HCV testing was targeted to IDU women, hence the HCV status was not known for many women. The pattern of baseline characteristics and missing data suggests that in East Europe many HIV diagnoses were during antenatal care, reflecting care delivery in this region [27]. Some women were still pregnant when audit data were collected, and outcome information was not available for some of these pregnancies. Finally, the study was not powered to investigate the impact of individual antiretrovirals, although this remains a key question for pregnant WLWH.

In conclusion, our analysis revealed heterogeneity in pregnancies and outcomes among WLWH in Europe. These differences highlight distinct approaches to the management of family planning and fertility needs among
WLWH across the European region. Further surveillance of the incidence and outcomes of pregnancies among WLWH is warranted to ensure equal access to sexual and reproductive health counselling and antenatal care.

Acknowledgments

We would like to thank all women living with HIV and clinicians caring for them for contributing to the EuroSIDA Study.

Author contributions: J.D.K, L.R., D.R, A.M and A.P.-M. conceived the study and planned the analysis. A.P.-M. performed statistical analysis and data interpretation. J.D.K and A.P.-M. wrote the first draft of the manuscript in collaboration with A.M. M.H.L, T.T., V.M.M., I.K., D.P., C.S., P.D., E.B., A.d'A.M., L.O., E.J., A.K., S.M., M.V., C.P., M.B., L.V. and A.C. contributed to patient recruitment and data collection, and to interpretation and presentation of results. A.M. supervised the project. All authors reviewed and approved the manuscript.

The multi-centre study group, EuroSIDA (national coordinators in parenthesis).

The multi-centre study group, EuroSIDA (national coordinators in parenthesis).

Albania: (A Harxhi), University Hospital Center of Tirana, Tirana. Argentina: (M Losso), M Kundro, Hospital JM Ramos Mejia, Buenos Aires. Austria: (B Schmied), Otto Wagner Hospital, Vienna; R Zangerle, Medical University Innsbruck, Innsbruck. Belarus: (I Karpov), A Vassilenko, Belarusian State Medical University, Minsk, Belarus; VM Mitsura, Gomel State Medical University, Gomel; D Paduto, Regional AIDS Centre, Svetlogorsk. Belgium: (N Clumeck), S De Wit, M Delforge, Saint-Pierre Hospital, Brussels; E Florence, Institute of Tropical Medicine, Antwerp; L Vandekerckhove, University Ziekenhuis Gent, Gent. Bosnia-Herzegovina: (V Hadziosmanovic), Klinicki Centar Univerziteta Sarajevo, Sarajevo. Croatia: (J Begovac), University Hospital of Infectious Diseases, Zagreb. Czech Republic: (L Machala), D Jilich, Faculty Hospital Bulovka, Prague; D Sedlacek, Charles University Hospital, Plzen. Denmark: G Kronborg, T Benfield, Hvidovre Hospital, Copenhagen; J Gerstoft, T Katzenstein, Rigshospitalet, Copenhagen; C Pedersen, IS Johansen, Odense University Hospital, Odense; L Ostergaard, Skejby Hospital, Aarhus, L Wiese, NF Moller, Sjællands Universitetshospital, Roskilde; L N Nielsen, Hillerod Hospital, Hillerod. Estonia: (K Zilmer), West-Tallinn Central Hospital, Tallinn; Jelena Smidt, Nakkusosakond Siseklinik, Kohtla-Järve. Finland: (I Aho), Helsinki University Hospital, Helsinki. France: (J-P Viard), Hôtel-Dieu, Paris; P-M Girard, Hospital Saint-Antoine, Paris; C Pradier, E Fontas, Hôpital de l'Archet, Nice; C Duvivier, Hôpital Necker-Enfants Malades, Paris. Germany: (J Rockstroh), Universitäts Klinik Bonn; G Behrens, Medizinische Hochschule Hannover; O Degen, University Medical Center Hamburg-Eppendorf, Infectious Diseases Unit, Hamburg; HJ Stellbrink, IPM Study Center, Hamburg; C Stephan, JW Goethe University Hospital, Frankfurt; J Bogner, Medizinische Poliklinik, Munich; G. Fätkenheuer, Universität Köln, Cologne. Georgia: (N Chkhartishvili) Infectious Diseases, AIDS & Clinical Immunology Research Center, Tbilisi. Greece: (H Sambatakou), Ippokration General Hospital, Athens; G Adamis, N Paissios, Athens General Hospital "G Gennimatas", Athens. Hungary: (J Szlávik), South-Pest Hospital Centre – National Institute for Infectology and Haematology, Budapest. Iceland: (M Gottfredsson), Landspitali University Hospital, Reykjavik. Ireland: (C Kelly), St. James’s Hospital, Dublin. Israel: (L Tau), D Turner, M Burke, Ichilov Hospital, Tel Aviv; E Shahar, G Hassoun, Rambam Medical Center, Haifa; H Elinav, M Haouzi, Hadassah University Hospital, Jerusalem; D Elbirt, AIDS Center (Neve Or), Jerusalem. Italy: (A D’Arminio Monforte), Istituto Di Clinica Malattie Infettive e Tropicale, Milan; R Esposito, I Mazeu, C Mussini, Università Modena, Modena; F Mazzotta, A Gabbotti, Ospedale S Maria Annunziata, Firenze; A Lazzarin, A Castagna, N Gianotti, Ospedale San Raffaele, Milan; M Galli, A Ridolfo, Osp. L. Sacco, Milan. Lithuania: (V Uzdaviniene) Vilnius University Hospital Santaros Klinikos, Vilnius; R Matulionyte, Vilnius University, Faculty of Medicine, Department of Infectious Diseases and Dermatovenereology, Vilnius, Lithuania. Luxembourg: (T Staub), R Hemmer, Centre Hospitalier, Luxembourg. Montenegro: (S Dragas), M Stevanovic, Clinical Center
of Montenegro, Podgorica. **Netherlands:** (P Reiss), Academisch Medisch Centrum bij de Universiteit van Amsterdam, Amsterdam. **North Macedonia:** (J Trajanovska), University Clinic for Infectious Diseases & Febrile Conditions, Mother Teresa 17, Skopje. **Norway:** (DH Reikvam), A Maeland, J Bruun, Oslo University Hospital, Ulleval. **Poland:** (B Knyisz), B Szetela, M Ingilot, Medical University, Wroclaw; E Bakowska, Centrum Diagnostyki i Terapii AIDS, Warsaw; R Flisik, A Grzeszczuk, Medical University, Bialystok; M Parczewski, K Maciejewska, B Aksak-Was, Medical University, Szczecin; M Beniowski, E Mularska, Osrodek Diagnostyki i Terapii AIDS, Chorzow; E Jablonowska, J Kamerys, K Wojcik, Wojewodzki Szpital Specjalistyczny, Lodz; I Mozer-Lisewska, B Rozplochowski, Poznan University of Medical Sciences, Poznan. **Portugal:** (A Zagalo), Hospital Santa Maria, Lisbon; K Mansinho, Hospital de Egas Moniz, Lisbon; F Maltez, Hospital Curry Cabral, Lisbon. **Romania:** (R Radoi), C Oprea, Carol Davila University of Medicine and Pharmacy Bucharest, Victor Babes Clinical Hospital for Infectious and Tropical Diseases, Bucharest. **Russia:** A Yakovlev, Medical Academy Botkin Hospital, St Petersburg; T Trofimora, Novgorod Centre for AIDS, Novgorod, I Khromova, Centre for HIV/AIDS & and Infectious Diseases, Kaliningrad; E Kuzovatova, Nizhny Novgorod Scientific and Research Institute of Epidemiology and Microbiology named after Academician I.N. Blokhina, Nizhny Novgorod; E Borodulina, E Vdoushkina, Samara State Medical University, Samara. **Serbia:** (J Rainin), The Institute for Infectious and Tropical Diseases, Belgrade. **Slovenia:** (J Tomazic), University Clinical Centre Ljubljana, Ljubljana. **Spain:** (JM Miro), M. Laguno, E. Martinez, F. Garcia, JL Blanco, M. Martinez-Rebollar, J. Mallolas, P Callau, J Rojas, A Inciarta, Hospital Clinic – IDIBAPS University of Barcelona, Barcelona; S Moreno, S. del Campo, Hospital Ramon y Cajal, Madrid; B Clotet, A Jou, R Paredes, J Puig, JM Llibre, JR Santos, Infectious Diseases Unit & IrisCaixa AIDS Research Institute, Hospital Germans Trias i Pujol, Badalona; P Domingo, M Gutierrez, G Mateo, MA Sambeat, Hospital Sant Pau, Barcelona; JM Laporte, Hospital Universitario de Alava, Vitoria-Gasteiz. **Sweden:** (V Svedhem), A Thalme, A Sonnerborg, Karolinska University Hospital, Stockholm; CJ Treutiger, Venhalsan-Sodersjukhuset, Stockholm; L Flamholc, Malmö University Hospital, Malmö. **Switzerland:** (K Kusejkou), R Weber, University Hospital Zurich; M Cavassini, University Hospital Lausanne; A Calmy, University Hospital Geneva; H Furrer, University Hospital Bern; M Battegay, University Hospital Basel; P Schmid, Cantonal Hospital St. Gallen. **Ukraine:** A Kuznetsova, Kharkov State Medical University, Kharkov; J Mikhalik, Crimean Republican AIDS centre, Simferopol; M Sliuszhynska, Lviv Regional HIV/AIDS Prevention and Control CTR, Lviv. **United Kingdom:** A Milinkovic, St. Stephen’s Clinic, Chelsea and Westminster Hospital, London; AM Johnson, E Simons, S Edwards, Mortimer Market Centre, London; A Phillips, MA Johnson, A Miro, Royal Free and University College Medical School, London (Royal Free Campus); C Orkin, Royal London Hospital, London; A Winston, Imperial College School of Medicine at St. Mary’s, London; A Clarke, Royal Sussex County Hospital, Brighton; C Leen, Western General Hospital, Edinburgh.

The following centers have previously contributed data to EuroSIDA: Medical University, Gdansk, Poland, Infectious Diseases Hospital, Sofia, Bulgaria, Hôpital de la Croix Rousse, Lyon, France, Hôpital de la Pitié-Salpêtrière, Paris, France, Unité INSERM, Bordeaux, France, Hôpital Edouard Herriot, Lyon, France, Bernhard Nocht Institut für Tropenmedizin, Hamburg, Germany, 1st I.K.A Hospital of Athens, Athens, Greece, Ospedale Riuniti, Divisione Malattie Infettive, Bergamo, Italy, Ospedale di Bolzano, Divisione Malattie Infettive, Bolzano, Italy, Ospedale Cotugno,III Divisione Malattie Infettive, Napoli, Italy, Dérer Hospital, Bratislava, Slovakia, Hospital Carlos III, Departamento de Enfermedades Infecciosas, Madrid, Spain, Kiev Centre for AIDS, Kiev, Ukraine, Luhansk State Medical University, Luhansk, Ukraine, Odessa Region AIDS Center, Odessa, Ukraine, St Petersburg AIDS Centre, St Petersburg, Russia, Infectology Centre of Latvia, Riga, Latvia, University of Roma la Sapienza, Rome, Italy, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani, Rome, Italy, Italy.

**EuroSIDA Steering Committee:** I Karpov, M Losso, J Lundgren, J Rockstroh, I Aho, LD Rasmussen, V Svedhem, G Wandeler, C Pradier, N Chkhartishvili, R Matulionyte, C Oprea, JD Kowalska, J Begovac, JM Miró, G Guaraldi, R Paredes. **Chair:** G Wandeler. **Co-Chair:** R Paredes. **Study lead:** A Miro. **EuroSIDA Coordinating Centre Staff:** L Peters, JF Larsen, A Bojesen, B Neesgaard, M Sather, D Raben, EV Hansen, D Kristensen, AH Fischer, SK Jensen. **Statistical Staff:** A Miro, A Phillips, J Reekie, A Cozzi-Lepri, S Amele, A Pelchen-Matthews, A Roen, ES Tusch, W Bannister.

**Funding:** EuroSIDA has received funding from ViIV Healthcare LLC, Janssen Scientific Affairs, Janssen R&D, Bristol-Myers Squibb Company, Merck Sharp & Dohme Corp, Gilead Sciences and the European Union’s Seventh Framework Programme for research, technological development and demonstration under EuroCoord grant agreement no 260694. The participation of centres from Switzerland has been supported by the Swiss National Science Foundation (Grant 148522). The study is also supported by a grant [grant number DNRF126] from the Danish National Research Foundation and by the International Cohort Consortium of Infectious Disease (RESPOND).
List of Supplementary materials:

Supplementary Table S1. Characteristics of women of reproductive age under follow-up in the three time periods, stratified by whether they reported ≥1 pregnancy in the time period

Supplementary Table S2. Characteristics of women with a pregnancy compared to those who did not report a pregnancy in the year, based on the annual pregnancy audits 1996 to 2015.

Supplementary Table S3. Characteristics of women with live births vs. spontaneous abortions or stillbirths between 1996 and 2014.

Supplementary Figure S1. Analysis of pregnancy outcomes.
References:

**Figure Captions:**

**Figure 1. Trends in pregnancies in Europe between 1996 and 2015.**

Proportions of women of reproductive age (≥16 and <50 years old, light grey bars), women with pregnancy information available (medium grey bars) and who reported at least one pregnancy (dark grey bars), by time period (TP1, 1996-2002; TP2, 2003-2009; TP3, 2010-2015) (a) or by region of Europe (b). The proportion of women who reported ≥1 pregnancy, stratified by time period and region, is shown in (c).

Note that women could contribute data to more than one time period.

Bars indicate 95% confidence intervals for the proportions.

Regions of Europe were defined as described [15] and include: South and Argentina: Argentina, Greece, Israel, Italy, Portugal and Spain; West/Central Europe: Austria, Belgium, France, Germany, Luxembourg and Switzerland; North Europe: Denmark, Finland, Iceland, Ireland, the Netherlands, Norway, Sweden and the United Kingdom; Central East Europe: Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Hungary, Poland, Romania, Serbia, Slovakia and Slovenia; and East Europe: Belarus, Estonia, Georgia, Latvia, Lithuania, Russia and the Ukraine.

**Figure 2. Factors associated with the odds of pregnancy (vs. no pregnancy).**

Adjusted odds ratios (aOR) of pregnancy are presented after adjusting for time period, age (as a continuous variable), smoking status, body mass index, previous pregnancy reported in EuroSIDA, region of Europe, baseline CD4 counts and viral load, time since HIV diagnosis, prior use of ART, hepatitis B (HBV) and hepatitis C (HCV) coinfection and prior AIDS.

Regions of Europe were defined as described in Figure 1.

Abbreviations: ART, anti-retroviral therapy; HBV, Hepatitis B virus; HCV, Hepatitis C virus; TP, time period; VL, viral load.
Figure 1.

(a) Proportion of women of reproductive age
Of these, proportion with pregnancy information
Of these, reported ≥1 pregnancy

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>% of women</td>
<td>94.4</td>
<td>73.9</td>
<td>92.2</td>
</tr>
<tr>
<td>Total number</td>
<td>2375</td>
<td>3772</td>
<td>4584</td>
</tr>
<tr>
<td>Number of</td>
<td>2241</td>
<td>3476</td>
<td>3835</td>
</tr>
<tr>
<td>Reproductive age</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>With information</td>
<td>1655</td>
<td>2595</td>
<td>2708</td>
</tr>
<tr>
<td>Reported ≥1</td>
<td>254</td>
<td>449</td>
<td>341</td>
</tr>
<tr>
<td>pregnancy</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(b) % of women

<table>
<thead>
<tr>
<th>Region</th>
<th>South</th>
<th>West/Central</th>
<th>North</th>
<th>Central East</th>
<th>East</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total number</td>
<td>1643</td>
<td>1201</td>
<td>815</td>
<td>659</td>
<td>1402</td>
</tr>
<tr>
<td>Number of</td>
<td>1568</td>
<td>1135</td>
<td>787</td>
<td>647</td>
<td>1398</td>
</tr>
<tr>
<td>Reproductive age</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>With information</td>
<td>1203</td>
<td>706</td>
<td>596</td>
<td>569</td>
<td>1143</td>
</tr>
<tr>
<td>Reported ≥1</td>
<td>195</td>
<td>140</td>
<td>140</td>
<td>110</td>
<td>321</td>
</tr>
<tr>
<td>pregnancy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(c) Time Period

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>N Total</td>
<td>254</td>
<td>449</td>
<td>341</td>
</tr>
<tr>
<td>All</td>
<td>1655</td>
<td>2595</td>
<td>2708</td>
</tr>
<tr>
<td>South</td>
<td>71</td>
<td>92</td>
<td>57</td>
</tr>
<tr>
<td>West/Central</td>
<td>80</td>
<td>59</td>
<td>23</td>
</tr>
<tr>
<td>North</td>
<td>63</td>
<td>72</td>
<td>40</td>
</tr>
<tr>
<td>Central East</td>
<td>22</td>
<td>60</td>
<td>48</td>
</tr>
<tr>
<td>East</td>
<td>18</td>
<td>166</td>
<td>173</td>
</tr>
</tbody>
</table>
Figure 1. Trends in pregnancies in Europe between 1996 and 2015.

Proportions of women of reproductive age (≥16 and <50 years old, light grey bars), women with pregnancy information available (medium grey bars) and who reported at least one pregnancy (dark grey bars), by time period (TP1, 1996-2002; TP2, 2003-2009; TP3, 2010-2015) (a) or by region of Europe (b). The proportion of women who reported ≥1 pregnancy, stratified by time period and region, is shown in (c).

Note that women could contribute data to more than one time period.

Bars indicate 95% confidence intervals for the proportions.

Regions of Europe were defined as described [15] and include: South and Argentina: Argentina, Greece, Israel, Italy, Portugal and Spain; West/Central Europe: Austria, Belgium, France, Germany, Luxembourg and Switzerland; North Europe: Denmark, Finland, Iceland, Ireland, the Netherlands, Norway, Sweden and the United Kingdom; Central East Europe: Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Hungary, Poland, Romania, Serbia, Slovakia and Slovenia; and East Europe: Belarus, Estonia, Georgia, Latvia, Lithuania, Russia and the Ukraine.
Figure 2. Factors associated with the odds of pregnancy (vs. no pregnancy).

Adjusted odds ratios (aOR) of pregnancy are presented after adjusting for time period, age (as a continuous variable), smoking status, body mass index, previous pregnancy reported in EuroSIDA, region of Europe, baseline CD4 cell counts (cells/µl), baseline viral load (copies/ml), time since HIV diagnosis, previously on ART, prior HBV, prior HCV, and prior AIDS.
CD4 counts and viral load, time since HIV diagnosis, prior use of ART, hepatitis B (HBV) and hepatitis C (HCV) coinfection and prior AIDS.

Regions of Europe were defined as described in Figure 1.

Abbreviations: ART, anti-retroviral therapy; HBV, Hepatitis B virus; HCV, Hepatitis C virus; TP, time period; VL, viral load.
**Supplementary Table S1. Characteristics of women of reproductive age under follow-up in the three time periods, stratified by whether they reported ≥1 pregnancy in the time period.**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pregnant in Time Period</td>
<td>Not Pregnant</td>
<td>P-value</td>
</tr>
<tr>
<td>Number under follow-up</td>
<td>254</td>
<td>1401</td>
<td></td>
</tr>
<tr>
<td>Age (Years)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (IQR)</td>
<td>30 (26, 33)</td>
<td>34 (30, 38)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Age group</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;30 years</td>
<td>131 (51.6)</td>
<td>361 (25.8)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>30 to &lt;40 years</td>
<td>118 (46.5)</td>
<td>775 (55.3)</td>
<td>0.0088</td>
</tr>
<tr>
<td>40 to &lt;50 years</td>
<td>5.2 (2.0)</td>
<td>265 (18.9)</td>
<td></td>
</tr>
<tr>
<td>Ethnic group</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White/Caucasian</td>
<td>175 (68.9)</td>
<td>1073 (76.6)</td>
<td>0.0088</td>
</tr>
<tr>
<td>Other/unknown</td>
<td>79 (31.1)</td>
<td>328 (23.4)</td>
<td></td>
</tr>
<tr>
<td>Risk group</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IDU</td>
<td>70 (27.6)</td>
<td>405 (28.9)</td>
<td>0.0813</td>
</tr>
<tr>
<td>Heterosexual</td>
<td>163 (64.2)</td>
<td>796 (56.8)</td>
<td></td>
</tr>
<tr>
<td>Other/unknown</td>
<td>21 (8.3)</td>
<td>125 (8.9)</td>
<td></td>
</tr>
<tr>
<td>Region of Europe c</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>South</td>
<td>71 (28.0)</td>
<td>512 (36.5)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>West/Central</td>
<td>80 (31.5)</td>
<td>405 (28.9)</td>
<td></td>
</tr>
<tr>
<td>North</td>
<td>63 (24.8)</td>
<td>301 (21.5)</td>
<td></td>
</tr>
<tr>
<td>Central East</td>
<td>22 (8.7)</td>
<td>163 (11.6)</td>
<td></td>
</tr>
<tr>
<td>East</td>
<td>18 (7.1)</td>
<td>20 (1.4)</td>
<td></td>
</tr>
<tr>
<td>Smoking Status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never smoked</td>
<td>16 (6.3)</td>
<td>130 (9.3)</td>
<td>0.0012</td>
</tr>
<tr>
<td>Current smoker</td>
<td>49 (19.3)</td>
<td>409 (29.2)</td>
<td></td>
</tr>
<tr>
<td>Past smoker</td>
<td>1 (0.4)</td>
<td>2 (0.1)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>188 (74.0)</td>
<td>860 (61.4)</td>
<td></td>
</tr>
<tr>
<td>BMI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Underweight</td>
<td>3 (1.2)</td>
<td>69 (4.9)</td>
<td>0.0094</td>
</tr>
<tr>
<td>Normal</td>
<td>55 (21.7)</td>
<td>393 (28.1)</td>
<td></td>
</tr>
<tr>
<td>Overweight</td>
<td>16 (6.3)</td>
<td>76 (5.4)</td>
<td></td>
</tr>
<tr>
<td>Obese</td>
<td>3 (1.2)</td>
<td>15 (1.1)</td>
<td></td>
</tr>
<tr>
<td>--------------------------</td>
<td>--------------------------</td>
<td>--------------------------</td>
<td></td>
</tr>
<tr>
<td><strong>N (%)</strong>^a</td>
<td><strong>N (%)</strong></td>
<td><strong>P-value</strong>^b</td>
<td><strong>N (%)</strong></td>
</tr>
<tr>
<td>Unknown</td>
<td>254</td>
<td>1401</td>
<td>449</td>
</tr>
<tr>
<td></td>
<td>177 (69.7)</td>
<td>848 (60.5)</td>
<td>201 (44.8)</td>
</tr>
</tbody>
</table>

**Baseline CD4 cell count (cells/µl)**

<table>
<thead>
<tr>
<th>Median (IQR)</th>
<th><strong>N (%)</strong></th>
<th><strong>P-value</strong></th>
<th><strong>N (%)</strong></th>
<th><strong>P-value</strong></th>
<th><strong>N (%)</strong></th>
<th><strong>P-value</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>337 (190, 441)</td>
<td>0.0003</td>
<td>481 (342, 630)</td>
<td>0.0167</td>
<td>455 (335, 633)</td>
<td>0.0261</td>
<td></td>
</tr>
<tr>
<td>260 (145, 400)</td>
<td>&lt;0.0001</td>
<td>22 (10.6)</td>
<td>0.0001</td>
<td>20 (5.9)</td>
<td>0.0001</td>
<td></td>
</tr>
<tr>
<td>≤200</td>
<td>270 (146, 385)</td>
<td>289 (170, 462)</td>
<td>&lt;0.0001</td>
<td>260 (160, 382)</td>
<td>0.0183</td>
<td></td>
</tr>
<tr>
<td>201 to 350</td>
<td>190 (96, 300)</td>
<td>112 (24.9)</td>
<td>&lt;0.0001</td>
<td>100 (29.3)</td>
<td>&lt;0.0001</td>
<td></td>
</tr>
<tr>
<td>351 to 500</td>
<td>695 (49.6)</td>
<td>831 (38.7)</td>
<td>&lt;0.0001</td>
<td>950 (40.1)</td>
<td>&lt;0.0001</td>
<td></td>
</tr>
<tr>
<td>&gt;500</td>
<td>809 (57.4)</td>
<td>1099 (51.2)</td>
<td>&lt;0.0001</td>
<td>1299 (54.9)</td>
<td>&lt;0.0001</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>143 (56.3)</td>
<td>100 (29.3)</td>
<td>&lt;0.0001</td>
<td>835 (39.4)</td>
<td>&lt;0.0001</td>
<td></td>
</tr>
</tbody>
</table>

**Baseline viral load**

<table>
<thead>
<tr>
<th>Controlled (&lt;400 cp/ml)</th>
<th><strong>N (%)</strong></th>
<th><strong>P-value</strong></th>
<th><strong>N (%)</strong></th>
<th><strong>P-value</strong></th>
<th><strong>N (%)</strong></th>
<th><strong>P-value</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>38 (15.0)</td>
<td>182 (53.4)</td>
<td>0.0001</td>
<td>1593 (67.3)</td>
<td>&lt;0.0001</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥400 copies/ml</td>
<td>234 (16.7)</td>
<td>0.1684</td>
<td>55 (4.7)</td>
<td>1299 (54.9)</td>
<td>&lt;0.0001</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>699 (49.9)</td>
<td>109 (29.3)</td>
<td>&lt;0.0001</td>
<td>553 (23.4)</td>
<td>&lt;0.0001</td>
<td></td>
</tr>
</tbody>
</table>

**Time since HIV diagnosis (years)**

<table>
<thead>
<tr>
<th>Median (IQR)</th>
<th><strong>N (%)</strong></th>
<th><strong>P-value</strong></th>
<th><strong>N (%)</strong></th>
<th><strong>P-value</strong></th>
<th><strong>N (%)</strong></th>
<th><strong>P-value</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>3.5 (1.3, 6)</td>
<td>5.6 (2.5, 8.9)</td>
<td>&lt;0.0001</td>
<td>9.5 (4.6, 16.0)</td>
<td>&lt;0.0001</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤2 years</td>
<td>78 (30.7)</td>
<td>179 (39.9)</td>
<td>&lt;0.0001</td>
<td>74 (21.7)</td>
<td>&lt;0.0001</td>
<td></td>
</tr>
<tr>
<td>2 - &lt;5 years</td>
<td>89 (29.1)</td>
<td>369 (17.2)</td>
<td>&lt;0.0001</td>
<td>371 (15.7)</td>
<td>&lt;0.0001</td>
<td></td>
</tr>
<tr>
<td>≥5 years</td>
<td>89 (49.9)</td>
<td>1213 (56.5)</td>
<td>&lt;0.0001</td>
<td>1717 (72.5)</td>
<td>&lt;0.0001</td>
<td></td>
</tr>
</tbody>
</table>

**Ever Exposed to any ART**

<table>
<thead>
<tr>
<th><strong>N (%)</strong></th>
<th><strong>P-value</strong></th>
<th><strong>N (%)</strong></th>
<th><strong>P-value</strong></th>
<th><strong>N (%)</strong></th>
<th><strong>P-value</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>160 (63.0)</td>
<td>0.0001</td>
<td>285 (63.5)</td>
<td>0.0001</td>
<td>266 (78.0)</td>
</tr>
</tbody>
</table>
| Ever Exposed to any cART (≥3 ARVs from any class)
| Yes       | 83 (32.7)   | 0.4394    | 250 (55.7)  | 0.0001    | 2014 (82.5) | <0.0001  |
| Prior HBV d
| Yes       | 2 (0.8)     | 0.4394    | 3 (0.7)     | <0.0001   | 1 (0.3)     | 0.0001    |
| Unknown   | 199 (78.3)  | 1037 (74) | 361 (80.4)  | 0.0001    | 1315 (55.6) | <0.0001   |
| Prior HCV e
| Yes       | 58 (22.8)   | 0.001     | 138 (30.7)  | 0.0001    | 1042 (44.0) | <0.0001   |
| Unknown   | 181 (71.3)  | 834 (59.5) | 268 (59.7)  | 0.0001    | 856 (36.2)  | <0.0001   |
|--------------------------|--------------------------|--------------------------|
| Pregnant in Time Period | Not Pregnant             | P-value                  | Pregnant in Time Period | Not Pregnant             | P-value                  | Pregnant in Time Period | Not Pregnant             | P-value                  |
| N (%) a                  | N (%)                    |                          | N (%)                   | N (%)                    |                          | N (%)                   | N (%)                    |                          |
| Number under follow-up   | 254                      | 1401                     |                          | 449                      | 2146                     |                          | 341                      | 2367                     |                          |

Prior AIDS f

<table>
<thead>
<tr>
<th></th>
<th>Pregnant</th>
<th>Not Pregnant</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No</td>
<td>221 (87.0)</td>
<td>1077 (76.9)</td>
<td>0.0034</td>
</tr>
<tr>
<td>Mild</td>
<td>22 (8.7)</td>
<td>208 (14.8)</td>
<td></td>
</tr>
<tr>
<td>Moderate</td>
<td>11 (4.3)</td>
<td>107 (7.6)</td>
<td></td>
</tr>
<tr>
<td>Severe</td>
<td>0 (0)</td>
<td>9 (0.6)</td>
<td></td>
</tr>
</tbody>
</table>

**Footnotes:**

- Values were calculated relative to January 1st of the first year when pregnancy information was available for each woman.
- Column percentages.
- Chi-squared P-values for proportions, or Wilcoxon signed rank test P-values for the continuous variables.
- Region of Europe includes South and Argentina: Argentina, Greece, Israel, Italy, Portugal and Spain; West/Central Europe: Austria, Belgium, France, Germany, Luxembourg and Switzerland; North Europe: Denmark, Finland, Iceland, Ireland, the Netherlands, Norway, Sweden and the United Kingdom; Central East Europe: Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Hungary, Poland, Romania, Serbia, Slovakia and Slovenia; and East Europe: Belarus, Estonia, Georgia, Latvia, Lithuania, Russia and the Ukraine.
- HBV positive if ever HBV surface antigen (HBsAg) positive prior to the analysis date.
- HCV positive if ever had a positive HCV antibody test, HCV RNA test, an HCV genotype assay or received HCV treatment.
- Prior AIDS-defining-diseases were classified as mild: candidiasis (oesophageal, bronchi, trachea, or lungs), mycobacterial infections, tuberculosis, cytomegalovirus infections, cryptosporidiosis, herpes simplex virus disease, Kaposi sarcoma, Pneumocystis jiroveci pneumonia and HIV wasting syndrome; moderate: bacterial pneumonia, coccidioidomycosis, cryptococcosis, invasive cervical cancer, AIDS dementia complex, focal brain lesions, histoplasmosis, isosporiasis, Mycobacterium avium complex, salmonella and toxoplasmosis; and severe: Progressive multifocal leukoencephalopathy and non-Hodgkin lymphoma (see [28]).

**Abbreviations:**

BMI, body mass index; cART, combination antiretroviral therapy; HBV, Hepatitis B virus; HCV, Hepatitis C virus; IDU, intravenous drug user; IQR, interquartile range.
Supplementary Table S2. Characteristics of women with a pregnancy compared to those who did not report a pregnancy in the year, based on the annual pregnancy audits 1996 to 2015.

<table>
<thead>
<tr>
<th>Number of pregnancy information audit items available</th>
<th>Pregnancy reported N (%)</th>
<th>Not pregnant N (%)</th>
<th>Unadjusted Odds Ratio</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time period</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TP1 - 1996 to 2002</td>
<td>319 (24.3)</td>
<td>5642 (25.6)</td>
<td>0.91 (0.79, 1.04)</td>
<td>0.16</td>
</tr>
<tr>
<td>TP2 - 2003 to 2009</td>
<td>576 (43.8)</td>
<td>8391 (38.0)</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td>TP3 - 2010 to 2015</td>
<td>420 (31.9)</td>
<td>8032 (36.4)</td>
<td>0.68 (0.60, 0.78)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Age group (years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;30</td>
<td>565 (43.0)</td>
<td>3462 (15.7)</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td>30 to &lt;40</td>
<td>663 (50.4)</td>
<td>10102 (45.8)</td>
<td>0.41 (0.36, 0.47)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>40 to &lt;50</td>
<td>87 (6.6)</td>
<td>8501 (38.5)</td>
<td>0.07 (0.06, 0.09)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Previous pregnancy in EuroSIDA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>403 (30.6)</td>
<td>3420 (15.5)</td>
<td>0.77 (0.59, 1.00)</td>
<td>0.052</td>
</tr>
<tr>
<td>Ethnic group</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White/Caucasian</td>
<td>1067 (81.1)</td>
<td>18208 (82.5)</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td>Other/unknown</td>
<td>248 (18.9)</td>
<td>3857 (17.5)</td>
<td>1.04 (0.87, 1.25)</td>
<td>0.64</td>
</tr>
<tr>
<td>Risk group</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IDU</td>
<td>339 (25.8)</td>
<td>6073 (27.5)</td>
<td>0.92 (0.78, 1.08)</td>
<td>0.29</td>
</tr>
<tr>
<td>Heterosexual</td>
<td>888 (67.5)</td>
<td>14301 (64.8)</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td>Other/unknown</td>
<td>88 (6.7)</td>
<td>1691 (7.7)</td>
<td>0.79 (0.60, 1.05)</td>
<td>0.10</td>
</tr>
<tr>
<td>Region of Europe</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>South</td>
<td>277 (21.1)</td>
<td>7504 (34.0)</td>
<td>0.57 (0.45, 0.72)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>West/Central</td>
<td>204 (15.5)</td>
<td>3509 (15.9)</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td>North</td>
<td>234 (17.8)</td>
<td>3736 (16.9)</td>
<td>0.99 (0.77, 1.28)</td>
<td>0.90</td>
</tr>
<tr>
<td>Central East</td>
<td>162 (12.3)</td>
<td>3506 (15.9)</td>
<td>0.76 (0.58, 0.99)</td>
<td>0.045</td>
</tr>
<tr>
<td>East</td>
<td>438 (33.3)</td>
<td>3810 (17.3)</td>
<td>1.88 (1.51, 2.33)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Smoking status</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never smoked</td>
<td>406 (30.9)</td>
<td>7367 (33.4)</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td>Current smoker</td>
<td>422 (32.1)</td>
<td>9067 (41.1)</td>
<td>0.91 (0.77, 1.08)</td>
<td>0.27</td>
</tr>
<tr>
<td>Past smoker</td>
<td>135 (10.3)</td>
<td>2539 (11.5)</td>
<td>0.91 (0.71, 1.15)</td>
<td>0.43</td>
</tr>
<tr>
<td>Unknown</td>
<td>352 (26.8)</td>
<td>3092 (14.0)</td>
<td>2.11 (1.79, 2.48)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Underweight (&lt;18.5)</td>
<td>63 (4.8)</td>
<td>1561 (7.1)</td>
<td>0.85 (0.64, 1.12)</td>
<td>0.2397</td>
</tr>
<tr>
<td>Normal (18.5-24.9)</td>
<td>598 (45.5)</td>
<td>12017 (54.5)</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td>Overweight (25-29.9)</td>
<td>164 (12.5)</td>
<td>3132 (14.2)</td>
<td>0.95 (0.77, 1.18)</td>
<td>0.65</td>
</tr>
<tr>
<td>Obese (&gt;30)</td>
<td>52 (4.0)</td>
<td>992 (4.5)</td>
<td>0.90 (0.62, 1.33)</td>
<td>0.81</td>
</tr>
<tr>
<td>Unknown</td>
<td>438 (33.3)</td>
<td>4363 (19.8)</td>
<td>1.98 (1.72, 2.27)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Baseline CD4 cell counts (cells/µL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤200</td>
<td>104 (7.9)</td>
<td>2727 (12.4)</td>
<td>0.72 (0.57, 0.90)</td>
<td>0.0042</td>
</tr>
<tr>
<td>201 to ≤500</td>
<td>560 (42.6)</td>
<td>9463 (42.9)</td>
<td>1.05 (0.92, 1.20)</td>
<td>0.44</td>
</tr>
<tr>
<td>&gt;500</td>
<td>529 (40.2)</td>
<td>9383 (42.5)</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>122 (9.3)</td>
<td>492 (2.2)</td>
<td>4.09 (3.29, 5.09)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Nadir CD4 cell counts (cells/µL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤200</td>
<td>428 (32.5)</td>
<td>10883 (49.3)</td>
<td>0.53 (0.46, 0.62)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>&gt;200</td>
<td>765 (58.2)</td>
<td>10690 (48.4)</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>122 (9.3)</td>
<td>492 (2.2)</td>
<td>3.20 (2.59, 3.96)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Baseline viral load (copies/mL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;400</td>
<td>636 (48.4)</td>
<td>13496 (61.2)</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td>≥400</td>
<td>440 (33.5)</td>
<td>6053 (29.5)</td>
<td>1.41 (1.24, 1.60)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Unknown</td>
<td>239 (18.2)</td>
<td>2066 (9.4)</td>
<td>2.32 (1.99, 2.72)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Time since HIV diagnosis (years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 2</td>
<td>281 (21.4)</td>
<td>1776 (8.0)</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td>2 to &lt;5</td>
<td>291 (22.1)</td>
<td>3607 (16.3)</td>
<td>0.52 (0.43, 0.62)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>≥5</td>
<td>743 (56.5)</td>
<td>16682 (75.6)</td>
<td>0.30 (0.25, 0.35)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Ever exposed to any ART</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>1020 (77.6)</td>
<td>19846 (89.9)</td>
<td>0.39 (0.34, 0.46)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Unknown</td>
<td>950 (72.2)</td>
<td>13627 (61.8)</td>
<td>1.78 (1.54, 2.06)</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

a. N refers to the number of pregnancy audits.
b. Prior HBV indicates a history of hepatitis B virus infection.
Data for 4217 women, of whom 912 were ever pregnant, with overall 1315 pregnancies between 1996 and 2015 (1217 between 1996 and 2014). The 4127 women reported altogether 23,380 items of pregnancy information between 1996 and 2015; women provided a median of 4 (IQR 2, 7; range 1-20) items of pregnancy information per person.

Variables were calculated relative to January 1st of the year in which the pregnancy information was reported.

Footnotes:

a Column percentages.

b HBV positive if ever HBV surface antigen (HBsAg) positive prior to the analysis date.

c HCV positive if ever had a positive HCV antibody test, HCV RNA test, an HCV genotype assay or received HCV treatment.

Abbreviations: HBV, Hepatitis B virus; HCV, Hepatitis C virus; IDU, intravenous drug user.
### Supplementary Table S3. Characteristics of women with live births vs. spontaneous abortions or stillbirths between 1996 and 2014.

<table>
<thead>
<tr>
<th></th>
<th>Live Birth</th>
<th>Stillborn or medical abortion</th>
<th>Total</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N (%)</td>
<td>N (%)</td>
<td>N (%)</td>
<td></td>
</tr>
<tr>
<td>Number under FU</td>
<td>690</td>
<td>110</td>
<td>800</td>
<td></td>
</tr>
<tr>
<td>Time period</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TP1 (1996 to 2002)</td>
<td>153 (22.2%)</td>
<td>35 (31.8)</td>
<td>188 (23.5%)</td>
<td>0.075</td>
</tr>
<tr>
<td>TP2 (2003 to 2009)</td>
<td>347 (50.3%)</td>
<td>46 (41.8)</td>
<td>393 (49.1%)</td>
<td></td>
</tr>
<tr>
<td>TP3 (2010 to 2014)</td>
<td>190 (27.5%)</td>
<td>29 (26.4)</td>
<td>219 (27.4%)</td>
<td></td>
</tr>
<tr>
<td>Previous pregnancy in EuroSIDA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>224 (32.5%)</td>
<td>28 (25.5)</td>
<td>252 (31.5%)</td>
<td>0.14</td>
</tr>
<tr>
<td>Age group</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;30 years</td>
<td>325 (47.1%)</td>
<td>35 (31.8)</td>
<td>360 (45.0%)</td>
<td>0.0046</td>
</tr>
<tr>
<td>30 to &lt;40 years</td>
<td>329 (47.7%)</td>
<td>64 (58.2)</td>
<td>393 (49.1%)</td>
<td></td>
</tr>
<tr>
<td>40 to &lt;50 years</td>
<td>36 (5.2%)</td>
<td>11 (10.0)</td>
<td>47 (5.9%)</td>
<td></td>
</tr>
<tr>
<td>Ethnic group</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White/Caucasian</td>
<td>562 (81.4%)</td>
<td>89 (80.9)</td>
<td>651 (81.4%)</td>
<td>0.89</td>
</tr>
<tr>
<td>Other/unknown</td>
<td>128 (18.6%)</td>
<td>21 (19.1)</td>
<td>149 (18.6%)</td>
<td></td>
</tr>
<tr>
<td>Risk group</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IDU</td>
<td>171 (24.8%)</td>
<td>28 (25.5)</td>
<td>199 (24.9%)</td>
<td>0.81</td>
</tr>
<tr>
<td>Heterosexual</td>
<td>479 (69.4%)</td>
<td>74 (67.3)</td>
<td>553 (69.1%)</td>
<td></td>
</tr>
<tr>
<td>Other/unknown</td>
<td>40 (5.8%)</td>
<td>8 (7.3)</td>
<td>48 (6.0%)</td>
<td></td>
</tr>
<tr>
<td>Region of Europe</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>South</td>
<td>133 (19.3%)</td>
<td>27 (24.5)</td>
<td>160 (20.0%)</td>
<td>0.043</td>
</tr>
<tr>
<td>West/Central</td>
<td>124 (18.0%)</td>
<td>18 (16.4)</td>
<td>142 (17.5%)</td>
<td></td>
</tr>
<tr>
<td>North</td>
<td>112 (16.2%)</td>
<td>28 (25.5)</td>
<td>140 (17.5%)</td>
<td></td>
</tr>
<tr>
<td>Central East</td>
<td>81 (11.7%)</td>
<td>11 (10.0)</td>
<td>92 (11.5%)</td>
<td></td>
</tr>
<tr>
<td>East</td>
<td>240 (34.8%)</td>
<td>26 (23.6)</td>
<td>266 (33.3%)</td>
<td></td>
</tr>
<tr>
<td>Smoking Status</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never smoked</td>
<td>216 (31.3%)</td>
<td>30 (27.3)</td>
<td>246 (30.8%)</td>
<td>0.031</td>
</tr>
<tr>
<td>Current smoker</td>
<td>187 (27.1%)</td>
<td>44 (40.0)</td>
<td>231 (28.9%)</td>
<td></td>
</tr>
<tr>
<td>Past smoker</td>
<td>78 (11.3%)</td>
<td>13 (11.8)</td>
<td>91 (11.4%)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>209 (30.3%)</td>
<td>23 (20.9)</td>
<td>232 (29.0%)</td>
<td></td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Underweight (&lt;18.5)</td>
<td>24 (3.5%)</td>
<td>2 (1.8)</td>
<td>26 (3.3%)</td>
<td>0.013</td>
</tr>
<tr>
<td>Normal (18.5-24.9)</td>
<td>296 (42.9%)</td>
<td>59 (53.6)</td>
<td>355 (44.4%)</td>
<td></td>
</tr>
<tr>
<td>Overweight (25-29.9)</td>
<td>68 (9.9%)</td>
<td>18 (16.4)</td>
<td>86 (10.8%)</td>
<td></td>
</tr>
<tr>
<td>Obese (&gt;30)</td>
<td>34 (4.9%)</td>
<td>3 (2.7)</td>
<td>37 (4.6%)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>268 (38.8%)</td>
<td>28 (25.5)</td>
<td>296 (37.0%)</td>
<td></td>
</tr>
<tr>
<td>Baseline CD4 (cells/μL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤200</td>
<td>49 (7.1%)</td>
<td>10 (9.1)</td>
<td>59 (7.4%)</td>
<td>0.31</td>
</tr>
<tr>
<td>201 - 500</td>
<td>289 (41.9%)</td>
<td>48 (43.6)</td>
<td>337 (42.1%)</td>
<td></td>
</tr>
<tr>
<td>≥500</td>
<td>267 (38.7%)</td>
<td>45 (40.9)</td>
<td>312 (39.0%)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>85 (12.3%)</td>
<td>7 (6.4)</td>
<td>92 (11.5%)</td>
<td></td>
</tr>
<tr>
<td>CD4 Nadir (cells/μL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤200</td>
<td>221 (32.0%)</td>
<td>37 (33.6)</td>
<td>258 (32.3%)</td>
<td>0.19</td>
</tr>
<tr>
<td>&gt;200</td>
<td>384 (55.7%)</td>
<td>66 (60.0)</td>
<td>450 (56.3%)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>85 (12.3%)</td>
<td>7 (6.4)</td>
<td>92 (11.5%)</td>
<td></td>
</tr>
<tr>
<td>Baseline VL (copies/mL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;400</td>
<td>317 (45.9%)</td>
<td>57 (51.8)</td>
<td>374 (46.8%)</td>
<td>0.042</td>
</tr>
<tr>
<td>≥400</td>
<td>219 (31.7%)</td>
<td>40 (36.4)</td>
<td>259 (32.4%)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>154 (22.3%)</td>
<td>13 (11.8)</td>
<td>167 (20.9%)</td>
<td></td>
</tr>
<tr>
<td>Time since HIV diagnosis (categories)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 2 years</td>
<td>181 (26.2%)</td>
<td>16 (14.5)</td>
<td>197 (24.6%)</td>
<td>0.029</td>
</tr>
<tr>
<td>2 - &lt;5 years</td>
<td>138 (20.0%)</td>
<td>24 (21.8)</td>
<td>162 (20.3%)</td>
<td></td>
</tr>
<tr>
<td>≥5 years</td>
<td>371 (53.8%)</td>
<td>70 (63.6)</td>
<td>441 (55.1%)</td>
<td></td>
</tr>
<tr>
<td>Ever Exposed to any ART</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>510 (73.9%)</td>
<td>90 (81.8)</td>
<td>600 (75.0%)</td>
<td>0.075</td>
</tr>
<tr>
<td>Ever Exposed to any cART (≥3 ARVs from any class)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>445 (64.5%)</td>
<td>80 (72.7)</td>
<td>525 (65.6%)</td>
<td>0.091</td>
</tr>
</tbody>
</table>
Variables were calculated relative to January 1st of the year in which the pregnancy was reported.

Footnotes:

a Column percentages.

b Region of Europe includes South and Argentina: Argentina, Greece, Israel, Italy, Portugal and Spain; West/Central Europe: Austria, Belgium, France, Germany, Luxembourg and Switzerland; North Europe: Denmark, Finland, Iceland, Ireland, the Netherlands, Norway, Sweden and the United Kingdom; Central East Europe: Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Hungary, Poland, Romania, Serbia, Slovakia and Slovenia; and East Europe: Belarus, Estonia, Georgia, Latvia, Lithuania, Russia and the Ukraine.

c HBV positive if ever HBV surface antigen (HBsAg) positive prior to the analysis date.

d HCV positive if ever had a positive HCV antibody test, HCV RNA test, an HCV genotype assay or received HCV treatment.

e Prior AIDS-defining-diseases were classified as mild: candidiasis (oesophageal, bronchi, trachea, or lungs), mycobacterial infections, tuberculosis, cytomegalovirus infections, cryptosporidiosis, herpes simplex virus disease, Kaposi sarcoma, Pneumocystis jiroveci pneumonia and HIV wasting syndrome; moderate: bacterial pneumonia, coccidioidomycosis, cryptococcosis, invasive cervical cancer, AIDS dementia complex, focal brain lesions, histoplasmosis, isosporiasis, Mycobacterium avium complex, salmonella and toxoplasmosis; and severe: Progressive multifocal leukoencephalopathy and non-Hodgkin lymphoma.

Abbreviations: cART, combination antiretroviral therapy; HBV, Hepatitis B virus; HCV, Hepatitis C virus; IDU, intravenous drug user.
Supplementary Figure S1. Analysis of pregnancy outcomes.

Outcomes of 1217 pregnancies reported between 1996 and 2014 by time period (TP1, 1996-2002; TP2, 2003-2009; TP3, 2010-2015) (a) or by region of Europe (b). Factors associated with the odds of a live birth (n=690)
compared to spontaneous abortions or stillbirths (n=110) \( (c) \), adjusting for all variables shown and in addition for smoking status, BMI, baseline CD4 counts, baseline viral load, time since HIV diagnosis and prior use of ART.

Abbreviations: ART, anti-retroviral therapy; BMI, body mass index; HCV, Hepatitis C virus; TP, time period.